LY3867070

LY3867070 is an **investigational oral small molecule drug** being studied for safety, tolerability, and pharmacokinetics in healthy participants. The drug is undergoing a Phase 1 clinical trial with both single-ascending and multiple-ascending dose arms, as well as an arm addressing drug-drug interactions. The primary outcomes are focused on treatment-emergent adverse events and serious adverse events, while secondary outcomes include measurement of systemic exposure (AUC, Cmax) and exploratory assessment of CYP1A1 gene expression changes. As of July 2025, **no specific mechanism of action, target, or therapeutic indication has been publicly disclosed**. The developer and trial sponsor is Eli Lilly and Company[1][3][5][7][9].

Other names

LY3867070LY-3867070LY 3867070